Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation

Pediatric Transplantation

Volumn 10, Issue 6, 2006, Pages 707-711

  Filler, G ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Drug metabolism; Drug drug interactions; Mycophenolic acid; Pharmacokinetic variability

Indexed keywords

CYCLOSPORIN A; DRUG METABOLITE; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

AGE DISTRIBUTION; AREA UNDER THE CURVE; CHILD; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; ENZYME INDUCTION; GRAFT REJECTION; HUMAN; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; NONHUMAN; TRANSPLANTATION;

ADOLESCENT; AREA UNDER CURVE; CHILD; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; TACROLIMUS; TRANSPLANTATION;

EID: 33746893369     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00553.x     Document Type: Conference Paper

References (46)

1. BENET LZ, CUMMINS CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001: 50 (Suppl. 1): S3-S11.
2. BENET LZ, CUMMINS CL, WU CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003: 4: 393-398.
3. MACFARLANE GD, VENKATARAMANAN R, MCDIARMID SV, et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatr Transplant 2001: 5: 119-124.
4. TANAKA E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998: 23: 247-255.
5. PRZEPIORKA D, BAMBLE D, HILSENBECK D, et al. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000: 26: 601-605.
6. MAY DG, PORTER J, WILKINSON GR, et al. Frequency distribution of dapsone-N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994: 55: 492-500.
7. CHRISTIANS U. Transport proteins and intestinal metabolism. P-glycoprotein and cytochrome P4503A. Ther Drug Monit 2004: 26: 104-106.
8. SYNOLD TW, DUSSAULT I, FORMAN BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 2001: 7: 584-590.
9. ZIMMERMANN C, GUTMANN H, HRUZ P, et al. Mapping of multidrug resistance-associated protein isoforms 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005: 33: 219-224.
10. MACHADO CG, CALADO RT, GARCIA AB, et al. Age-related changes of the multidrug resistance p-glycoprotein function in normal human peripheral blood T-lymphocytes. Brz J Med Biol Res 2003: 36: 1653-1657.
11. BRENNER SS, KLOTZ U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004: 60: 97-102.
12. FAKHOURY M, LITALIEN C, MEDARD Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005: 33: 1603-1607.
13. SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003: 4: 2325-2345.
14. EUGUI EM, MIRKOVICH A, ALLISON A. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991: 33: 175-183.
15. BENFIELD MR, STABLEIN D, TEJANI A. Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999: 3: 27-32.
16. http://spitfire.emmes.com/study/ped/resources/annlrept2005.pdf, page 41. accessed on 19 November 2005
17. SCHÜTZ E, SHIPKOVA M, ARMSTRONG VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998: 30: 1185-1187.
18. ETTENGER R, MENSTER B, WARSHAW B, POTTER D, NICHOLS A. Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): Final report of the pediatric MMF study group (PMMFSG). 16th Annual Meeting American Society of Transplant Physicians 1997: 287 (Abstract).
19. WEBER LT, SHIPKOVA M, LAMERSDORF T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998: 9: 1511-1520.
20. WEBER LT, LAMERSDORF T, SHIPKOVA M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999: 21: 498-506.
21. ATCHESON BA, TAYLOR PJ, KIRKPATRICK CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004: 26: 284-286.
22. ZUCKER K, ROSEN A, TSAROUCHA A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997: 5: 225-232.
23. HUBNER GI, EISMANN R, SZIEGOLEIT W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999: 21: 536-539.
24. FILLER G, LAMPE D, MAI I, STREHLAU J, EHRICH JHH. Reduced dosing of MMF in combination with tacrolimus for steroid resistant, vascular rejection in renal allografts. Transpl Int 1998: 11 (Suppl. 1): 82-85.
25. FILLER G, ZIMMERING M, MAI I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000: 14: 100-104.
26. ZUCKER K, TSAROUCHA A, OLSON L, ESQUENAZI V, TZAKIS A, MILLER J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999: 21: 35-43.
27. FILLER G, FOSTER J, BERARD R, MAI I, LEPAGE N. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004: 36: 1327-1331.
28. SAWAMOTO T, VAN GELDER T, CHRISTIANS U, et al. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in Mdck and MDR1-MDCK monolayers. J Heart Lung Transplant 2001: 20: 234-235.
29. FILLER G, LEPAGE N, DELISLE B, MAI I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 2001: 23: 514-519.
30. PAPE L, FROEDE K, STREHLAU J, EHRICH JH, OFFNER G. Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant 2003: 7: 302-304.
31. KAMISAKO T, LEIER I, CUI Y, et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 1999: 30: 485-490.
32. UNDRE NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003: 18 (Suppl 1): i12-15.
33. RENDERS L, STEINBACH R, VALERIUS T, SCHOCKLMANN HO, KUNZENDORF U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004: 27: 181-185.
34. KUYPERS DR, VERLEDEN G, NAESENS M, VANRENTERGHEM Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 2005: 78: 81-88.
35. FILLER G, LEPAGE N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol 2004: 19: 962-965.
36. HUBNER GI, EISMANN R, SZIEGOLEIT W. Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung 2000: 50: 936-940.
37. JACQZ-AIGRAIN E, KHAN SHAGHAGHI E, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000: 14: 95-99.
38. DAVID-NETO E, PEREIRA ARAUJO LM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003: 18: 266-272.
39. LANGMAN LJ, LEGATT DF, YATSCOFF RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995: 41: 295-299.
40. BUDDE K, GLANDER P, BAUER S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000: 38: 1213-1216
41. FILLER G, FEBER J, LEPAGE N, WEILER G, MAI I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002: 6: 411-418.
42. KUYPERS DR, CLAES K, EVENEPOEL P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003: 43: 866-880.
43. FILLER G, MAI I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000: 22: 169-173.
44. PAWINSKI T, HALE M, KORECKA M, FITZSIMMONS WE, SHAW LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002: 48: 1497-1504.
45. WEBER LT, SCHUTZ E, LAMERSDORF T, et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant.1999: 14 (Suppl. 4): 34-35.
46. FILLER G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004: 17: 120-125.